Literature DB >> 16770231

Preoperative evaluation of patients with malignant pleural mesothelioma: role of integrated CT-PET imaging.

Mylene T Truong1, Edith M Marom, Jeremy J Erasmus.   

Abstract

Malignant pleural mesothelioma (MPM) is an uncommon neoplasm arising from mesothelial cells of the pleura. The prognosis is poor with a median survival of 8 to 18 months after diagnosis. Multimodality regimens combining chemotherapy, radiotherapy, immunotherapy, and surgery are being used more frequently in patient management. Extrapleural pneumonectomy is the surgical treatment of choice in 10% to 15% of patients who present with resectable disease and is reported to prolong survival. Accurate staging is important to distinguish patients who are resectable from those requiring palliative therapy. Integrated computed tomography-positron emission tomography (CT-PET) increases the accuracy of overall staging in patients with MPM and significantly improves the selection of patients for curative surgical resection. Specifically, CT-PET detects more extensive disease involvement than that shown by other imaging modalities and is particularly useful in identifying occult distant metastases. This article reviews aspects of imaging performed in the initial staging of patients with MPM according to the International Mesothelioma Interest Group staging system and will emphasize the appropriate role of CT-PET imaging in determining the T, N, and M descriptors.

Entities:  

Mesh:

Year:  2006        PMID: 16770231     DOI: 10.1097/00005382-200605000-00006

Source DB:  PubMed          Journal:  J Thorac Imaging        ISSN: 0883-5993            Impact factor:   3.000


  7 in total

1.  BTS statement on malignant mesothelioma in the UK, 2007.

Authors: 
Journal:  Thorax       Date:  2007-11       Impact factor: 9.139

2.  Positron emission tomography in mesothelioma patients.

Authors:  Gaia Grassetto; Domenico Rubello
Journal:  Mol Imaging Biol       Date:  2009-03-25       Impact factor: 3.488

3.  Primary lesions were more 18F-FDG avid in patients with distant spread than in those without extensive disease.

Authors:  Victor H Gerbaudo; Scott Britz-Cunningham
Journal:  Mol Imaging Biol       Date:  2009 Nov-Dec       Impact factor: 3.488

4.  PET-guided dose escalation tomotherapy in malignant pleural mesothelioma.

Authors:  Andrei Fodor; Claudio Fiorino; Italo Dell'Oca; Sara Broggi; Marcella Pasetti; Giovanni Mauro Cattaneo; Luigi Gianolli; Riccardo Calandrino; Nadia Gisella Di Muzio
Journal:  Strahlenther Onkol       Date:  2011-10-28       Impact factor: 3.621

5.  Lymph node dissection in primary intrahepatic malignant mesothelioma: case report and implications for diagnosis and therapy.

Authors:  Bettina M Buchholz; Ines Gütgemann; Hans-Peter Fischer; Marcus Gorschlüter; Andreas Türler; Jörg C Kalff; Andreas Hirner; Jens Standop
Journal:  Langenbecks Arch Surg       Date:  2009-03-12       Impact factor: 3.445

Review 6.  Malignant mesothelioma: current status and perspective in Japan and the world.

Authors:  Seiki Hasegawa; Fumihiro Tanaka
Journal:  Gen Thorac Cardiovasc Surg       Date:  2008-07-08

7.  Prognostic value of 18F-FDG PET/CT in patients with malignant pleural mesothelioma.

Authors:  S T Lee; M Ghanem; R A Herbertson; S U Berlangieri; A J Byrne; K Tabone; P Mitchell; S R Knight; M Feigen; A M Scott
Journal:  Mol Imaging Biol       Date:  2009-03-28       Impact factor: 3.488

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.